Skip to main content
Premium Trial:

Request an Annual Quote

ProMetic to Develop Synthetic Affinity Ligand for Novartis' Vaccine Program

NEW YORK (GenomeWeb News) — Synthetic protein drug developer ProMetic Biosciences will develop a synthetic ligand affinity for Novartis, the company said today.
 
PBL, a subsidiary of ProMetic Life Sciences, said Novartis Vaccines has hired it to screen chemical libraries for ligands that may be used to purify a new vaccine product Novartis currently has in clinical trials.
 
PBL, based in Montreal, said it will conduct the screenings using its Mimetic protein replacement system at its labs at the Cambridge Science Park, in Cambridge, UK.
 
Financial terms of the agreement were not released.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.